Incyte Corporation (INCY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Incyte Corporation stock (INCY) is currently trading at $92.23. Incyte Corporation PE ratio is 14.14. Incyte Corporation PS ratio (Price-to-Sales) is 3.51. Analyst consensus price target for INCY is $107.59. WallStSmart rates INCY as Buy.
- INCY PE ratio analysis and historical PE chart
- INCY PS ratio (Price-to-Sales) history and trend
- INCY intrinsic value — DCF, Graham Number, EPV models
- INCY stock price prediction 2025 2026 2027 2028 2029 2030
- INCY fair value vs current price
- INCY insider transactions and insider buying
- Is INCY undervalued or overvalued?
- Incyte Corporation financial analysis — revenue, earnings, cash flow
- INCY Piotroski F-Score and Altman Z-Score
- INCY analyst price target and Smart Rating
Incyte Corporation
📊 No data available
Try selecting a different time range
INCY Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Incyte Corporation (INCY)
INCY trades at a significant discount to its Graham intrinsic value of $299.99, offering a 67% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Incyte Corporation (INCY) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Overall metrics suggest strong investment potential with favorable risk/reward.
Incyte Corporation (INCY) Key Strengths (8)
Growing significantly faster than its price suggests
Every $100 of shareholder equity generates $30 in profit
Earnings per share surging 43.60% year-over-year
Keeps $25 of every $100 in revenue as net profit
104.68% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $26 kept per $100 revenue
Strong revenue growth at 27.80% annually
Supporting Valuation Data
Incyte Corporation (INCY) Areas to Watch (2)
Premium pricing at 3.5x book value
Revenue is fairly priced at 3.51x sales
Incyte Corporation (INCY) Detailed Analysis Report
Overall Assessment
This company scores 83/100 in our Smart Analysis, earning a A- grade. Out of 10 metrics analyzed, 8 register as strengths (avg 9.4/10) while 2 fall into concern territory (avg 5.0/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on PEG Ratio, Return on Equity, EPS Growth. Valuation metrics including PEG Ratio (0.32) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 29.90%, Operating Margin at 25.60%, Profit Margin at 25.00%. Growth metrics are encouraging with Revenue Growth at 27.80%, EPS Growth at 43.60%.
The Bear Case
The primary concerns are Price/Book, Price/Sales. Some valuation metrics including Price/Sales (3.51), Price/Book (3.50) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 29.90% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 27.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of PEG Ratio and Return on Equity makes a compelling case at current levels. The key risk is Price/Book, but the overall fundamental picture is positive with a clear path to maintaining or improving the current A- grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
INCY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
INCY's Price-to-Sales ratio of 3.51x trades at a deep discount to its historical average of 30.48x (0th percentile). The current valuation is 99% below its historical high of 246.47x set in Nov 2009, and 0% above its historical low of 3.51x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Incyte Corporation (INCY) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Incyte Corporation is a strong growth company balancing expansion with improving profitability. Revenue reached 5.1B with 28% growth year-over-year. Profit margins are strong at 25.0%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 28% YoY, reaching 5.1B. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 2990.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Incyte Corporation maintain 28%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Incyte Corporation.
Bottom Line
Incyte Corporation offers an attractive blend of growth (28% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(29 last 3 months)
| Insider | Type | Shares |
|---|---|---|
MORRISSEY, MICHAEL JAMES EVP, Head of Tech. Operations | Sell | -429 |
| Insider | Type | Shares |
|---|---|---|
ISSA, MOHAMED KHAIRIE EVP, Head of US Oncology | Sell | -10,856 |
| Insider | Type | Shares |
|---|---|---|
ISSA, MOHAMED KHAIRIE EVP, Head of US Oncology | Sell | -8,264 |
| Insider | Type | Shares |
|---|---|---|
STEIN, STEVEN H EVP & Chief Medical Officer | Sell | -15,634 |
Data sourced from SEC Form 4 filings
Last updated: 8:25:19 AM
About Incyte Corporation(INCY)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.